Restored immune response to an MHC-II-restricted antigen in tumor-bearing hosts after elimination of regulatory T cells

Journal of Pediatric Surgery

Volumn 39, Issue 6, 2004, Pages 941-946

  Nicholl, Michael ^b   Lodge, Andrew ^b   Brown, Ian ^b   Sugg, Sonia L ^b   Shilyansky, Joel ^a  

^a CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^b NONE

Author keywords

Cancer; CD25; immunotherapy; T cell; tolerance

Indexed keywords

INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY;

ALLOGENEIC RESTRICTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; HOST; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; LYMPH NODE CELL; LYMPHATIC DRAINAGE; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOTHERAPY; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C3H; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, RADIATION-INDUCED; RECEPTORS, INTERLEUKIN-2; RIBOSOMAL PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTE SUBSETS;

EID: 3042667799     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2004.02.049     Document Type: Article

References (50)

1. Soling A., Schurr P., Berthold F. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res. 19:1999;2205-2209
2. Van Waes C., Urban J.L., Rothstein J.L., et al. Highly malignant tumor variants retain tumor-specific antigens recognized by T-cells. J Exp Med. 164:1986;1547-1564
3. Smyth M.J., Godfrey D.I., Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2:2001;293-299
4. Staveley-O'Carroll K., Sotomayor E., Montgomery J., et al. Induction of antigen-specific T cell anergy An early event in the course of tumor progression. PNAS. 95:1998;1178-1183
5. Tindle R.W. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2:2002;59-65
6. Ikeda H., Old L.J., Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13:2002;95-109
7. Schreiber H., Wu T.H., Nachman J., et al. Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol. 10:2000;351-357
8. Berinstein N. Overview of therapeutic vaccination approaches for cancer. Semin Oncol. 30:2003;1-8
9. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 21:2003;807-839
10. Mortarini R., Piris A., Maurichi A., et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 63:2003;2535-2545
11. Ochsenbein A.F. Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther. 9:2002;1043-1055
12. Ochsenbein A.F., Sierro S., Odermatt B., et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 411:2001;1058-1064
13. Appleman L.J., Boussiotis V.A. T cell anergy and costimulation. Immunol Rev. 192:2003;161-180
14. Spiotto M.T., Yu P., Rowley D.A., et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17:2002;737-747
15. Wilcox R.A., Flies D.B., Zhu G., et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 109:2002;651-659
16. Ke Y., Kapp L.M., Kapp J.A. Inhibition of tumor rejection by gammadelta T cells and IL-10. Cell Immunol. 221:2003;107-114
17. Wilson S.B., Delovitch T.L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol. 3:2003;211-222
18. Green D.R., Droin N., Pinkoski M. Activation-induced cell death in T cells. Immunol Rev. 193:2003;70-81
19. Krueger A., Fas S.C., Baumann S., et al. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev. 193:2003;58-69
20. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol. 21:2003;685-711
21. Shevach E.M. CD4+ CD25+ suppressor T cells More questions than answers. Nat Rev Immunol. 2:2002;389-400
22. + suppressor T cells. Immunol Rev. 182:2001;58-67
23. + regulatory T cells prevent graft rejection CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol. 168:2002;1080-1086
24. + regulatory T cells in vivo. J Exp Med. 198:2003;249-258
25. Jordan M.S., Boesteanu A., Reed A.J., et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol. 2:2001;301-306
26. Lohr J., Knoechel B., Jiang S., et al. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol. 4:2003;664-669
27. McHugh R.S., Shevach E.M. Cutting edge Depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol. 168:2002;5979-5983
28. Edinger M., Hoffmann P., Ermann J., et al. CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 9:2003;1144-1150
29. Laurie K.L., Van Driel I.R., Gleeson P.A. The role of CD4+CD25+ immunoregulatory T cells in the induction of autoimmune gastritis. Immunol Cell Biol. 80:2002;567-573
30. Javia L.R., Rosenberg S.A. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother. 26:2003;85-93
31. Woo E.Y., Yeh H., Chu C.S., et al. Cutting edge Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 168:2002;4272-4276
32. Woo E.Y., Chu C.S., Goletz T.J., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:2001;4766-4772
33. Beck-Engeser G.B., Monach P.A., Mumberg D., et al. Point mutation in essential genes with loss or mutation of the second allele Relevance to the retention of tumor-specific antigens. J Exp Med. 194:2001;285-300
34. Monach P.A., Meredith S.C., Siegel C.T., et al. A unique tumor antigen produced by a single amino acid substitution. Immunity. 2:1995;45-59
35. Seung L.P., Seung S.K., Schreiber H. Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res. 55:1995;5094-5100
36. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells A common basis between tumor immunity and autoimmunity. J Immunol. 163:1999;5211-5218
37. Sakaguchi S., Sakaguchi N., Shimizu J., et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 182:2001;18-32
38. Hoffmann P., Ermann J., Edinger M., et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 196:2002;389-399
39. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 99:2002;3493-3499
40. Wolf A.M., Wolf D., Steurer M., et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 9:2003;606-612
41. Sasada T., Kimura M., Yoshida Y., et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies Possible involvement of regulatory T cells in disease progression. Cancer. 98:2003;1089-1099
42. Liyanage U.K., Moore T.T., Joo H.G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 169:2002;2756-2761
43. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 300:2003;339-342
44. Kaech S.M., Ahmed R. Immunology. CD8 T cells remember with a little help. Science. 300:2003;263-265
45. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 300:2003;337-339
46. Bourgeois C., Rocha B., Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 297:2002;2060-2063
47. Bourgeois C., Veiga-Fernandes H., Joret A.M., et al. CD8 lethargy in the absence of CD4 help. Eur J Immunol. 32:2002;2199-2207
48. Janssen E.M., Lemmens E.E., Wolfe T., et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 421:2003;852-856
49. Giuntoli R.L., Lu J., Kobayashi H., et al. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. JR 2nd Clin Cancer Res. 8:2002;922-931
50. Gao F.G., Khammanivong V., Liu W.J., et al. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res. 62:2002;6438-6441